Aurobindo Pharma Ltd - Company Profile
Powered by
All the data and insights you need on Aurobindo Pharma Ltd in one report.
- Save hours of research time and resources with
our up-to-date Aurobindo Pharma Ltd Strategy Report
- Understand Aurobindo Pharma Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Aurobindo Pharma Ltd (Aurobindo) is a global pharmaceutical company that manufactures generic formulations, active pharmaceutical ingredients (APIs) and specialty products. The company’s product portfolio is spread over seven key therapeutic areas, including antibiotics antiretrovirals (ARVs), cardiovascular, central nervous systems (CNS), anti-diabetics, gastro-enterologicals, and anti-infectives.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D team focuses on developing complex formulations, niche oral, sterile, biosimilars, specialty injectable products, APIs and peptide based drugs. Product pipeline spans across oncology and Immunology. It employs more than 1,500 scientists and analysts in product development. It had many products under development in oncology and hormones, followed by two cancer biosimilars, three depot injections, one vaccine, topicals (33), transdermal patches (10), inhalers (eight) and nasals (nine). It has nine R&D centers out of which, five are in India and four in the US . It also has 24 state-of-the-art manufacturing and packaging facilities which are approved by regulatory agencies such as US FDA, EU GMP, South Africa-MCC, UK MHRA, Health Canada, Brazil ANVISA and WHO. In FY2023, Aurobindo launched 34 products, including 17 injectables in the US; received approvals for 19 ANDAs, including seven injectables. As of March 2023, the Company filed 774 ANDAs in total of which 565 have received final approvals and 34 have got tentative approvals which includes eight ANDAs that are tentatively approved under the US President’s Emergency Plan for AIDS Relief (PEPFAR) and 175 ANDAs which are currently under review. The company also had 276 US DMFs filings.
Business Segments
Overview
Aurobindo is a vertically integrated company with approximately 10.9% of its API requirement met in-house. It is one of the leading API manufacturing companies globally. The segment has presence across beta lactams and non-beta lactams and provides both sterile and non-sterile penicillin and cephalosporins with penams. - Major customers include innovator and large generic companies.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells generic formulations in the US. It offers non-penicillin and non-cephalosporin products. - Operates one manufacturing facilities in the US views product innovation as a critical growth driver for the segment. In line with this approach, for the FY2023, the company launched 34 products including orals, injectables, OTC and various branded divisions.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers antiretroviral medicines in various growth markets through participation in worldwide tenders floated by various international bodies.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells generic formulations in Europe. Views acquisitions as a major growth driver for the segment.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Manufactures and sells generic formulations in Latin America, Canada, South Africa and East Africa. - Operates eight key formulation facilities in India and one facility in Brazil.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward